RxDoctor Payments Data

Nicole Akers, MD

Family Medicine · Wahoo, NENPI 1114305083

Payments from drug & device makers

$2,607in general payments, 2019–2025

Across 168 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$691
  • Johnson & Johnson$236
  • Mylan Specialty L.p.$189
  • Pfizer$172
  • Novo Nordisk$147
  • Amgen$135
  • plus $1K from 30 others

What the payments were for

  • Food & beverage$2,607100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,607 in reported general payments places this provider in the 80th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$3,733
Medicare patients
23
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$58,240
EliquisApixaban79$47,196
YupelriRevefenacin25$37,030
FarxigaDapagliflozin Propanediol44$30,333
JardianceEmpagliflozin29$27,702
MyrbetriqMirabegron77$26,944
Formoterol Fumarate39$19,385
XareltoRivaroxaban33$16,959
Breo ElliptaFluticasone/Vilanterol22$8,813
RestasisCyclosporine16$7,735
NamzaricMemantine Hcl/Donepezil Hcl13$7,446
Xtampza ErOxycodone Myristate28$6,669
BelsomraSuvorexant12$5,681
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,005
JanuviaSitagliptin Phosphate15$4,106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$147$58,24061 claims
PfizerEliquis$172$47,19679 claims
Mylan Specialty L.p.Yupelri$189$37,03025 claims
Boehringer IngelheimJardiance, Stiolto Respimat$24$32,70640 claims
AstraZenecaFarxiga$115$30,33344 claims
Astellas Pharma US IncMyrbetriq$12$26,94477 claims
Johnson & JohnsonXarelto$236$16,95933 claims
AbbVieRestasis, Namzaric$691$15,18029 claims
MerckBelsomra, Januvia$39$9,78727 claims
GSKBreo Ellipta$48$8,81322 claims
NovartisEntresto$26$3,63321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Wahoo

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →